Guido Trezeguet Renatti

Guido Trezeguet Renatti

Auto-generated profile, based on publicly available information

Guido Trezeguet Renatti

Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Liver Transplantation
Verified
Journal Article
Closed access
GRGuido Trezeguet Renatti
Guido Trezeguet Renatti
NRNatalia Riva
Natalia Riva
JMJulia Minetto
Julia Minetto
HRHayellen Reijenstein
Hayellen Reijenstein
MGMaria Gole
Maria Gole
OIOscar Imventarza
Oscar Imventarza
Avoidance of steroids in pediatric liver transplantation may reduce toxicity and morbidity. The aim of this study was to analyze the feasibility of a steroid-free tacrolimus-basiliximab immunosuppression scheme, the risk factors associated with steroid requirement, and safety parameters. Patients who underwent liver transplantation for biliary atresia between 2011 and 2019 were included and followed for 6 months after transplantation. Immunosuppression consisted of tacrolimus-based treatment with basiliximab induction. Steroid-free survival was estimated, and risk factors for steroid requirement were evaluated using multivariate Cox regression analysis. A total of 76 patients were included, of whom 42 (55.3%) required steroids (>14 d) due to biopsy-proven acute rejection (47.6%, n = 20), instability in liver function tests (35.7%, n = 15), tacrolimus-related adverse drug reactions (14.3%, n = 6), or other reasons (bronchospasm episode, n = 1). Steroid-free survival was 45.9% (95% CI, 35.9–58.8). Independent factors associated with steroid requirement included tortuosity in tacrolimus trough levels (≥1.76 vs. <1.76: HR 5.8, 95% CI, 2.6–12.7; p < 0.001) and mean tacrolimus trough levels (≥ 6.4 ng/mL vs. < 6.4 ng/mL: HR 0.4, 95% CI, 0.2–0.7; p = 0.002). The rate of bacterial and viral infections was comparable between patients with and without steroids, although in the former group, cytomegalovirus infection developed earlier (p = 0.03). Patients receiving steroids had higher total cholesterol, LDL, and HDL levels (p < 0.05) during follow-up, but no changes in the height Z-score were observed 1 year after transplantation. Basiliximab induction in combination with tacrolimus-based treatment avoided steroid requirements in 45% of the patients. Tacrolimus variability and trough levels below 6.4 ng/mL independently increased the risk of steroid requirement. Further efforts should be focused on personalizing immunosuppressive treatment.

31 March 2026 in Liver Transplantation
Verified
Journal Article
Closed access
GRGuido Trezeguet Renatti
Guido Trezeguet Renatti
AAAgostina Arrigone
Agostina Arrigone
CCCatalina Costas
Catalina Costas
JMJulia Minetto
Julia Minetto
ABAndrea Bosaleh
Andrea Bosaleh
PSPaula Schaiquevich
Paula Schaiquevich
Surveillance biopsy is essential to detect graft rejection that remains silent to conventional liver function tests (LFTs), allowing tailored immunosuppression. The benefit of detecting subclinical biopsy-proven acute rejection (BPAR) comes at the cost of subjecting all pediatric recipients to an invasive procedure, including those who could potentially be safely spared if accurately identified as low risk of rejection using sensitive and noninvasive biomarkers of graft injury. We evaluated the ability of donor-derived cell-free DNA (dd-cfDNA) to rule out BPAR in pediatric liver transplant (LT) patients and its role in biopsy decision-making when used alongside LFTs. A clinical decision-making process combining LFTs and dd-cfDNA to identify low-risk rejection patients was developed using data from 98 patients under surveillance and 40 patients who underwent for-cause biopsy. Sixty BPAR events were recorded, and almost half of them (46.7%) were classified as subclinical BPAR (subBPAR). Only dd-cfDNA distinguished subBPAR from BPAR-free cases ( p =0.02), demonstrating a sensitivity of 96.7% (95% CI, 88.6–99.4) and a specificity of 34.6% (95% CI, 25.0–45.7) at a threshold of 1.9%. According to the decision-making process, patients with LFTs below the upper limit of normal and dd-cfDNA <1.9% would be spared from liver biopsy. Considering a BPAR prevalence of 43.4% in the study cohort, the negative and positive predictive values were 93.1% and 53.2%, respectively. In this large pediatric study, we demonstrate for the first time that low dd-cfDNA levels can reliably identify liver transplant patients at low risk of rejection, improving the tailoring of surveillance biopsies when used alongside LFTs.